| Test | Method | Patientsa/ studies | Sensitivity, % | Specificity, % | Interference by other bladder conditions | Reference |
| PMF1 | MSP | 118/1 | 65 | 95 | No | [58, 62] | Myopodin | MSP | 164/1 | 65 | 80 | No | [57] | RASSF1A | MSP | 24/1 | 50 | 100 | Not done | [70] | DAPK, RARβ, E-cadherin, and p16 | MSP | 39/1 | 91 | 76 | Not done | [71] | IRF8, p14, and sFRP1 | qMSP | 49/1 | 87 | 95 | No information | [63] | MYO3A, CA10, NKX6-2, DBC1, and SOX11 or PENK | qMSP | 238/1 | 85 | 95 | No | [64] | GDF15, TMEFF2, and VIM | qMSP | 110/1 | 94 | 90 | Not done | [72] | APC, RASSF1A, and p14ARF | MSP | 66/1 | 87 | 100 | No | [73] | DAPK, BCL2, and TERT | qMSP | 57/1 | 78 | 100 | Not done | [42, 74] | CDKN2A, ARF, MGMT, and GSTP1 | qMSP | 269/1 | 69 | 100 | No | [41, 75] | RASSF1A, p14, and E-cadherin | MSP | 66/1 | 80 | 100 | Not done | [76] | ZNF154, HOXA9, POU4F2, and EOMES | MS-HRM | 174/1 | 84 | 96 | No | [38, 65] | TWIST1 and NID2 | qMSP | 278/1 | 90 | 93 | No | [66] | APC, RASFF1A, RARB, DBC1, SFRP1, SFRP2, SFRP4, SFRP5 | qMSP | 146/1 | 52 | 100 | No | [67] | SFRP1, SFRP2, SFRP4, SFRP5, VIF-1, and DKK3 | MSP | 264/1 | 61.1 | 93.3 | Not done | [50, 68] | BCL2 and hTERT | qMSP | 213/1 | 76 | 98 | No | [21] | RASSF1a, E-cad, and APC | qMSP | 104/1 | 69 | 60 | No | [39, 69] | SALL3, CFTR, ABCC6, HPR1, RASSF1A, MT1A, RUNX3, ITGA4, BCL2, ALX4, MYOD1, DRM, CDH13, BMP3B, CCNA1, RPRM, MINT1, and BRCA1 | MSP | 159/1 | 92 | 88 | No | [77] |
|
|